Here are 1-2 brief analogies for RAPT Therapeutics:

• Vertex Pharmaceuticals for immunology, but currently in clinical trials. (RAPT is developing oral small molecule drugs for immune-mediated diseases, similar to how Vertex has found success with oral small molecules for cystic fibrosis, but RAPT's products are still in human trials.)

• An early-stage Incyte, focused on new targets for inflammatory diseases and cancer. (Incyte is an established biotech company with a focus on oncology and inflammatory diseases, often using small molecules. RAPT operates in similar therapeutic areas, also with small molecules, but is earlier in its development with novel targets.)

• RPTQ-565: An investigational oral Flt3 inhibitor currently in clinical development for the treatment of various cancers.
• RPTQ-171: An investigational oral CCR4 antagonist currently in clinical development for inflammatory diseases, including atopic dermatitis and asthma.

RAPT Therapeutics (symbol: RAPT) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for inflammatory diseases and cancer. As a company in the research and development phase, it does not currently have commercial products on the market and therefore does not have major customers in the traditional sense of companies or individuals purchasing its products or services.

Its business model revolves around advancing drug candidates through clinical trials. Potential future revenue streams, if successful, would typically come from:

1. Collaboration or licensing agreements with larger pharmaceutical companies (who would then be partners or licensees, rather than direct customers).
2. Eventual commercialization of approved drugs, where the "customers" would be healthcare providers, distributors, pharmacies, or wholesalers, rather than individuals directly.

Therefore, RAPT Therapeutics does not have a list of major current customers.

Brian Wong, M.D., Ph.D. President and Chief Executive Officer

Dr. Wong is a physician/scientist with over 25 years of experience leading organizations in innovative drug development. Prior to joining RAPT Therapeutics, he served as Senior Vice President, Research at Five Prime Therapeutics, which was subsequently acquired by Amgen. Before Five Prime, Dr. Wong was a Director in the Inflammation Disease Biology Area at Roche, where he oversaw the discovery and supported the development of Roche's autoimmune disease portfolio, encompassing over 20 programs from discovery to late-stage clinical development and approval. He also held various leadership roles at Rigel Pharmaceuticals. Dr. Wong is also listed as a founder of one other company and became a Venture Partner at The Column Group in 2022.

Rodney Young Chief Financial Officer and Secretary

Mr. Young brings more than 30 years of executive management and corporate finance experience to RAPT Therapeutics. Most recently, he served as Chief Financial Officer of Cellerant Therapeutics, Inc., a private clinical-stage company. Previously, he was Chief Financial Officer and Vice President of Finance and Administration of StemCells, Inc., a public biotechnology company, where he was responsible for raising over $200 million in financing. Earlier in his career, Mr. Young worked as an investment banker at Lehman Brothers and SG Cowen, leading financing and merger and acquisition transactions focused in the healthcare, biotechnology, and pharmaceutical sectors.

Dirk Brockstedt, Ph.D. Chief Scientific Officer

Dr. Brockstedt joined RAPT Therapeutics in January 2018 and has over 20 years of experience across all stages of discovery. He has co-authored more than 50 scientific papers and is a named inventor on seven issued patents and several pending applications.

William Ho, M.D., Ph.D. Chief Medical Officer

Dr. Ho joined RAPT Therapeutics in 2015, bringing extensive experience in clinical immunotherapy and the translational and clinical development of novel cancer therapeutics. Prior to RAPT, he served as Vice President of Clinical Development at Igenica Biotherapeutics and as a Senior Medical Director in Exploratory Clinical Development (BioOncology) at Genentech for seven years.

Gwen Carscadden Chief Human Resources Officer

Ms. Carscadden joined RAPT in April 2022, contributing over 30 years of extensive experience in building and leading high-quality human resource teams. Before RAPT, she served as Chief People Officer at Intersect ENT, a commercial-stage medical technology company.

The key risks to RAPT Therapeutics' business are primarily associated with the inherent challenges of clinical-stage biotechnology companies, specifically centered on clinical trial outcomes, financial sustainability, and market competition.

1. Clinical Trial Failure and Regulatory Hurdles: RAPT Therapeutics faces significant risks related to the success of its clinical trials and regulatory approvals. This was prominently demonstrated by the discontinuation of its lead asset, zelnecirnon (RPT193), in late 2024. The U.S. Food and Drug Administration (FDA) placed a clinical hold on its Phase 2b trial for atopic dermatitis and Phase 2a trial for asthma due to a serious adverse event involving liver failure in one patient, which was potentially related to the drug. This led to the termination of the zelnecirnon program and a substantial drop in the company's stock price. As a clinical-stage company, RAPT's pipeline candidates are subject to lengthy, expensive development processes with uncertain outcomes, and the results of earlier studies may not predict future trial success.
2. Cash Burn and Need for Additional Capital: RAPT Therapeutics has a history of significant losses and anticipates continued substantial losses as it progresses its drug candidates through development. While the company recently strengthened its cash position with a $250 million offering, future cash burn for pivotal clinical trials remains a considerable risk. The ability to maintain a sufficient cash runway is crucial, and the need to raise additional capital, potentially through issuing new shares or incurring debt, could dilute existing shareholder value or increase debt burden.
3. Intense Competition: The biopharmaceutical industry is highly competitive, and RAPT Therapeutics faces competition from numerous companies developing biologics and small molecule drugs for inflammatory diseases and cancer. Although RAPT's candidate, ozureprubart, has shown promising Phase 2 data in chronic spontaneous urticaria, the company operates in markets with significant existing and emerging competitors. The failure of a lead asset like zelnecirnon further concentrates the company's efforts on fewer candidates, intensifying the competitive pressure on its remaining pipeline.

The advancement of competing novel oral therapies, particularly TYK2 inhibitors, for the treatment of atopic dermatitis. Should these therapies demonstrate compelling efficacy and safety profiles in ongoing clinical trials, they could establish a new standard of care for oral non-JAK treatment, potentially limiting the future market opportunity for RAPT’s lead candidate, RPT193, in this indication.

RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on developing therapies for inflammatory diseases and oncology. The addressable markets for their main products or services are as follows:

• RPT904 (targeting Chronic Spontaneous Urticaria): The global chronic spontaneous urticaria market size was valued at approximately USD 779.28 million in 2024 and is projected to reach approximately USD 1,541.41 million by 2032.
• RPT904 (targeting Food Allergy): null
• FLX475 (targeting Oncology): The global oncology drugs market size was valued at USD 201.75 billion in 2023 and is projected to grow from USD 220.80 billion in 2024 to USD 518.25 billion by 2032.

1. Advancement and Potential Commercialization of Tivumecirnon (FLX475) in Oncology: Tivumecirnon, an oral CCR4 antagonist, is RAPT's lead oncology drug candidate and is in Phase 2 clinical trials. It is being evaluated as both a monotherapy and in combination with pembrolizumab (Keytruda) for advanced cancers. Positive Phase 2 data in checkpoint inhibitor-experienced head and neck squamous cell carcinoma (HNSCC) were announced in April 2024, showing promising objective response rates that compare favorably to anti-PD-1 monotherapy. Further expansion into other tumor types, such as gastric cancer and non-small cell lung cancer, along with potential partnerships for development outside of the Hanmi territory, could drive future revenue if it progresses to market approval.
2. Progression of Ozureprubart (RPT904) in Allergic Inflammatory Diseases: Ozureprubart, a long-acting anti-IgE antibody, is being developed for allergic inflammatory diseases. RAPT initiated a Phase 2b prestIgE trial in food allergy in late 2025, with top-line data anticipated in the first half of 2027. Additionally, RAPT and its partner Jemincare reported positive topline Phase 2 data for ozureprubart in chronic spontaneous urticaria (CSU), demonstrating comparable efficacy and safety to omalizumab. The companies plan to engage regulatory agencies to discuss potential Phase 3 registrational pathways for CSU. Successful advancement through these clinical stages and subsequent market entry or licensing deals would be a significant revenue driver.
3. Development and Launch of Next-Generation CCR4 Antagonists for Inflammatory Diseases: Following the termination of its zelnecirnon (RPT193) program in November 2024 due to FDA clinical holds, RAPT Therapeutics is focusing on developing next-generation CCR4 compounds with improved safety margins for inflammatory diseases. The company expects to identify a new lead candidate in the first half of 2025. Successful preclinical and clinical development of these new compounds could lead to future product launches and revenue generation.
4. Strategic In-licensing Opportunities for Clinical-Stage Assets: RAPT is actively pursuing in-licensing opportunities for clinical-stage assets to diversify its pipeline. Successful execution of such agreements could bring new revenue streams to the company through development milestones, royalties, or direct product sales from these acquired assets.

Share Issuance

• In October 2025, RAPT Therapeutics priced an underwritten public offering of 8,333,334 shares of common stock at $30.00 per share, with expected gross proceeds of approximately $250.0 million.
• In December 2024, the company completed a private placement, selling 100,000,000 shares of common stock at $0.85 per share and pre-funded warrants for 76,452,000 shares at $0.8499 per pre-funded warrant, yielding net proceeds of $143.0 million.
• In December 2022, RAPT Therapeutics completed an underwritten public offering of 4,338,104 shares of common stock, generating approximately $75.0 million in net proceeds.
• In June 2021, RAPT Therapeutics closed an underwritten public offering of 4,356,060 shares of common stock at $33.00 per share, resulting in aggregate gross proceeds of approximately $143.7 million.

Inbound Investments

• In December 2024, RAPT Therapeutics entered into a license agreement with Shanghai Jemincare Pharmaceutical Co., Ltd. for its drug candidate RPT904, receiving a $35.0 million upfront license fee. This agreement also includes potential future milestone payments of up to $672.5 million and tiered royalty payments on net sales.

Capital Expenditures

• Capital expenditures are primarily reflected within the company's research and development and general and administrative expenses, with increases or decreases in "facilities costs" noted in various financial reports.